logologo

Popular Boards

1 Mentions
Cory K. Mayfield, Ioanna K. Bolia, Cailan Lindsay Feingold | The American Journal of Sports Medicine | (2026)
Primary Link Pubmed DOI Openalex

Abstract

While peptide therapy may possess significant therapeutic and regenerative potential, it is critical that orthopaedic and sports medicine providers understand the current lack of evidence to support the clinical use of these peptides. Importantly, information regarding the indications, dosing, frequency, and duration of treatment remains unknown. Despite the popularity of these peptides in mainstream media and among patients, significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients.

Tags

Sample Definition And Size

This paper is a narrative review; it does not involve a primary sample or number of subjects. Instead, it synthesizes existing biochemical and clinical studies on injectable peptide therapies, including BPC‑157, TB‑4/TB‑500, CJC‑1295 + ipamorelin, tesamorelin, and GHK‑Cu ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41476424/?utm_source=openai)).

Study Type

Narrative review ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41476424/?utm_source=openai)).

Conflicts Of Interest

J.N.L. received speaking fees from Stryker and hospitality payments from Innocoll Biotherapeutics. G.R.H. received consulting fees from Arthrex. S.C.G. received speaking fees from Arthrex; consulting fees from Biomet, Zimmer, and Exactech; royalties from Zimmer; and holds stock or stock options in Kelvi. AOSSM checked disclosures against the Open Payments Database but disclaims independent investigation or liability ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41476424/?utm_source=openai)).

Results Summary

BPC‑157 showed potential benefits in tendon and muscle repair, but human evidence is limited to a single flawed case series. TB‑4/TB‑500 promoted angiogenesis and tissue repair in preclinical models; no human orthopaedic data exist, and they are banned in sports. CJC‑1295 + ipamorelin improved maximum tetanic tension in murine models of glucocorticoid‑induced muscle loss. Tesamorelin, approved for HIV‑associated lipodystrophy, lacks orthopaedic evidence. GHK‑Cu showed promise in wound healing and anti‑inflammatory effects, but no clinical data support its use in musculoskeletal conditions ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/41476424/?utm_source=openai)).

Referenced In

Lee Johnson
a month ago
A Scientific Review of Claims made by RFK Jr.

Claim: Peptides are Safe and Effective, and Were Unfairly Restricted

Verdict: False and misleading, with a small grain of truth.

“I’m a big fan of peptides. I’ve used them myself, and used them with really good effect – you know, on a couple of injuries. [...] There were 19 peptides that were formulated by compounding pharmacies, during the Biden Administration. They illegally moved those to category 2, which says ‘do not formulate.’ [...] They’re not supposed to do that unless there’s a safety signal, and they didn’t have a safety signal.”

RFK Jr. on the Joe Rogan Experience, February 27th, 2026: www.youtube.com

With the news that RFK Jr. is trying to lift restrictions on peptides, his comments just over a month ago on Joe Rogan are worth looking at in detail.

RFK Jr. claims that these peptide treatments are effective, that they were restricted without justification and that there was no “safety signal,” which in the context of the discussion is understood to mean “a major adverse event, signalling risk.”

What Actually Happened to Peptides

As a ProPublica article explains, efforts to regulate “compounding” pharmacies (which can create custom-made drugs for patients) ended up requiring the FDA to make a list of approved ingredients. But this took the FDA a long time.

After over 60 tragic deaths in 2012, they were forced to “rush” a solution – at least by FDA standards.

They eventually made three categories – safe, too risky, or not enough evidence – and started working through their list. This was still slow, but by 2023, they decided that peptides were “too risky.”

The Evidence on Peptides

So, what do we know about their risks and benefits?

In two words: not enough. While research suggests that some of them are likely helpful, data is scarce and we don’t know enough about the risks. There are plausible risks of immune responses, problems at the injection site and impurities in the drugs.

What the FDA Actually Did

The FDA did in fact review the safety of peptides. Finding the same lack of evidence as the paper cited above, they noted some potential risks, but really emphasized the minimal human data.

However, one grain of truth in RFK’s claim is that major adverse events seem rare. The FDA notes this on page 40 – the adverse event reporting systems show no issues.

Read Full Post
2